Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

919
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
919
Cancer Vaccines01:30

Cancer Vaccines

345
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
345
Development of Immunocompetence01:22

Development of Immunocompetence

294
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
294
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Vaccinations01:51

Vaccinations

44.1K
Overview
44.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

[Management of systemic lupus erythematosus-Including secondary antiphospholipid syndrome, fertility and pregnancy : S3 guidelines of the German Society for Rheumatology and Clinical Immunology and the German Society for Neurology (DGN), German Society for Internal Medicine (DGIM), German Cardiac Society (DGK), Society for Thrombosis and Hemostasis Research (GTH), German Society for Hematology and Medical Oncology (DGHO), German Society for Pediatric and Adolescent Medicine (DGKJ), Society for Pediatric and Adolescent Rheumatology (GKJR), German Society for Nephrology (DGfN), German Society for Pneumology and Ventilation Medicine (DGP), German Rheumatism League National Association, Lupus Erythematosus Self-help Community, German Dermatological Society (DDG). Version: 1.2].

Zeitschrift fur Rheumatologie·2025
Same author

[Diagnosis and treatment of ANCA-associated vasculitis : S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for ENT Medicine and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]

Zeitschrift fur Rheumatologie·2025
Same author

[Diagnosis and treatment of ANCA-associated vasculitis : SHORT VERSION of the S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for Otorhinolaryngology and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]

Zeitschrift fur Rheumatologie·2025
Same author

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Nature communications·2025
Same author

Macrophage colony-stimulating factor receptor/CD115<sup>+</sup> non-classical monocytes are expanded in systemic lupus erythematosus and associated with lupus nephritis.

Scandinavian journal of rheumatology·2024
Same author

Correction: An immunogenomic exome landscape of triple positive primary antiphospholipid patients.

Genes and immunity·2024

相关实验视频

Updated: Jun 12, 2025

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.2K

[在免疫抑制下进行冠状病毒疫苗接种]

R Hasseli-Fräbel1, C Kneitz2, R E Voll3

  • 1Sektion für Rheumatologie und Klinische Immunologie, Universitätsklinikum Münster, Münster, Deutschland.

Zeitschrift fur Rheumatologie
|September 23, 2024
PubMed
概括

患有炎症性类风湿性疾病的患者对COVID-19疫苗接种有良好的反应和耐受性. 大多数人实现了血清转化,即使在免疫抑制下,也没有增加疾病爆发或新的自身免疫问题.

关键词:
在B细胞枯竭的过程中接种COVID-19疫苗的时间炎症性类风湿性疾病是一种炎症性类风湿性疾病.在SARS-CoV-2中.血清转换是一种血清转换.

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

305

相关实验视频

Last Updated: Jun 12, 2025

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.2K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

305

科学领域:

  • 类风湿病学 类风湿病学
  • 传染性疾病 传染性疾病
  • 免疫学 免疫学 免疫学

背景情况:

  • 严重急性呼吸道综合征冠状病毒2 (SARS-CoV-2) 构成重大威胁,特别对免疫功能低下的人来说.
  • 关于COVID-19疫苗接种在患有炎性类风湿性疾病 (IRDs) 的患者中耐受性和有效性的数据有限,这些患者在流行病开始时接受免疫调节或免疫抑制.

研究的目的:

  • 评估IRD患者COVID-19疫苗接种的反应和耐受性.
  • 在这个队列中评估疫苗接种后疾病恶化或新的自身免疫现象的风险.

主要方法:

  • 对IRD患者COVID-19疫苗接种现有研究和队列数据的审查.
  • 在初始疫苗接种系列后,分析血清转化率.
  • 监测疾病爆发和新出现的自身免疫性疾病.

主要成果:

  • 大多数IRD患者 (不包括B细胞枯竭患者) 在接种两剂COVID-19疫苗后实现了血清转化.
  • 没有观察到潜在的风湿性疾病恶化症的显著增加.
  • 接种疫苗后没有报告新的自身免疫现象.

结论:

  • COVID-19疫苗接种通常耐受良好,并且在大多数炎症性类风湿性疾病患者中有效诱导免疫反应.
  • 这些发现支持对IRD患者的疫苗接种策略,即使是那些接受免疫抑制疗法的人,也要仔细考虑B细胞枯竭的个体.